Cholesterol moves in the blood on different lipoprotein particles, and the balance between LDL and HDL helps shape cardiovascular risk. This page maps how cholesterol levels vary across countries and age groups, including the large shares of adults in the U.S. and Europe with elevated readings. You’ll also explore how lifestyle factors and conditions like obesity, smoking, and type 2 diabetes shift lipid profiles—and how therapies can lower LDL toward guideline targets.
Key Takeaways
- LDL cholesterol is 70-80% carried by low-density lipoprotein particles in human plasma
- HDL cholesterol constitutes about 20-30% of total circulating cholesterol
- Cholesterol synthesis in the liver accounts for 70-80% of total body cholesterol production daily
- Desirable LDL <100 mg/dL per AHA guidelines for low risk
- Target LDL <70 mg/dL for very high CVD risk patients
- HDL <40 mg/dL men or <50 mg/dL women considered low risk factor
- According to the CDC, approximately 93 million U.S. adults aged 20 and older have elevated total cholesterol levels above 200 mg/dL
- The World Health Organization reports that high cholesterol contributes to 2.6 million deaths annually worldwide, representing 4.4% of all global deaths
- In Europe, the European Heart Network states that 54% of adults have total cholesterol levels above the recommended 5 mmol/L threshold
- High cholesterol increases CVD risk by 2.5-fold per 1 mmol/L LDL rise
- Each 38.7 mg/dL LDL reduction lowers major vascular events by 22%
- Low HDL (<40 mg/dL men) triples coronary heart disease risk
- Daily cholesterol intake averages 300-500 mg in Western diets
- Obesity increases LDL cholesterol by 10-15% per 10 kg weight gain
- Smoking raises LDL by 5-10% and lowers HDL by 10%
High LDL raises heart disease risk, and statins along with newer options can significantly lower LDL levels.
Related reading
01 · Category
Biological Mechanisms30 stats
01
LDL cholesterol is 70-80% carried by low-density lipoprotein particles in human plasma
02
HDL cholesterol constitutes about 20-30% of total circulating cholesterol
03
Cholesterol synthesis in the liver accounts for 70-80% of total body cholesterol production daily
04
HMG-CoA reductase enzyme regulates 90% of hepatic cholesterol biosynthesis rate
05
LDL particles have a density of 1.019-1.063 g/mL and diameter 18-25 nm
06
Cholesterol efflux capacity of HDL is mediated by ABCA1 transporter, removing 4-5% of cellular cholesterol per cycle
07
PCSK9 protein degrades 50-70% of LDL receptors daily in hepatocytes
08
SREBP-2 transcription factor induces 30 genes involved in cholesterol homeostasis
09
Cholesterol absorption in intestine is 40-60% efficient via NPC1L1 transporter
10
VLDL particles secrete 2-3 mg cholesterol per hour into plasma from liver
11
ApoB-100 protein is present on 90% of plasma lipoproteins containing cholesterol
12
Reverse cholesterol transport removes 5-10 grams of cholesterol daily via HDL
13
Cholesterol crystal formation in plaques involves 20-30% volume in advanced atherosclerosis
14
LCAT enzyme esterifies 70% of plasma cholesterol on HDL particles
15
Niemann-Pick C1 protein regulates 50% of lysosomal cholesterol export
16
CETP transfers 80% of cholesteryl esters from HDL to VLDL/LDL
17
Mevalonate pathway produces 1 gram of cholesterol per day in adults
18
OxLDL induces foam cell formation via CD36 receptor in 60% of macrophages
19
SR-B1 mediates selective uptake of 20-50% HDL cholesteryl esters in liver
20
ACAT2 esterifies 90% of cholesterol in enterocytes for chylomicron assembly
21
LXR agonists upregulate ABCA1 by 10-fold increasing efflux
22
Cholesterol 7-alpha-hydroxylase (CYP7A1) initiates 50% of bile acid synthesis
23
ApoE polymorphism affects 20-30% variation in LDL levels
24
Sphingomyelinase activates 40% of LDL aggregation in plaques
25
Farnesyl pyrophosphate intermediates inhibit LDL receptor by 70%
26
HDL maturation involves PLTP transferring 60% phospholipids
27
Familial hypercholesterolemia FH heterozygotes have 2-3 fold elevated LDL
28
NPC2 protein transfers cholesterol at rate of 1000 molecules/second
29
Oxidized phospholipids on LDL activate TLR4 in 50% of endothelial cells
30
ABCG5/G8 transporters limit intestinal absorption to 50% maximum
Interpretation
Biological Mechanisms Interpretation
From a biological mechanisms perspective, most cholesterol balance hinges on liver-driven synthesis and particle handling, with 70 to 80% produced daily in the liver and HMG-CoA reductase controlling about 90% of that rate while HDL removes only 4 to 5% per cycle via ABCA1.
02 · Category
Clinical Guidelines And Levels24 stats
01
Desirable LDL <100 mg/dL per AHA guidelines for low risk
02
Target LDL <70 mg/dL for very high CVD risk patients
03
HDL <40 mg/dL men or <50 mg/dL women considered low risk factor
04
Non-HDL goal <130 mg/dL for moderate risk per NCEP ATP III
05
Fasting lipid panel recommended every 4-6 years starting age 20
06
Total cholesterol 200-239 mg/dL borderline high
07
LDL 160-189 mg/dL high, warrants lifestyle intervention
08
Triglycerides <150 mg/dL normal, >500 mg/dL very high per AHA
09
Cascade screening for FH targets 1st degree relatives 80% yield
10
Apolipoprotein B target <90 mg/dL for high risk
11
Lp(a) >50 mg/dL considered risk enhancer per 2018 AHA
12
Risk assessment using PCE calculator 10-year ASCVD risk threshold 7.5%
13
Children of FH parents screened age 0-10, LDL >190 mg/dL diagnostic
14
Statin intensity high if LDL drop ≥50%, moderate 30-50%
15
ACC/AHA recommends lipid panel every 5 years age 40-75
16
ESC guideline LDL <55 mg/dL very high risk post-ACS
17
Optimal triglycerides <100 mg/dL for insulin resistance prevention
18
Direct LDL measurement preferred if triglycerides >400 mg/dL
19
HDL ≥60 mg/dL protective against CVD per NCEP
20
Universal screening lipids age 9-11 and 17-21 per AAP
21
Risk enhancers include high LDL-P >1000 nmol/L
22
Target apoB <80 mg/dL very high risk ESC 2019
23
Nonfasting lipids acceptable for initial screening per EAS
24
LDL ≥190 mg/dL in adults <40 initiates high intensity statin
Interpretation
Clinical Guidelines And Levels Interpretation
Clinical guidelines emphasize aiming for lower LDL targets, with a desirable level under 100 mg/dL for low risk and a much stricter target under 70 mg/dL for very high CVD risk patients, while HDL below 40 mg/dL in men or below 50 mg/dL in women flags an unfavorable risk pattern.
03 · Category
Epidemiology And Prevalence30 stats
01
According to the CDC, approximately 93 million U.S. adults aged 20 and older have elevated total cholesterol levels above 200 mg/dL
02
The World Health Organization reports that high cholesterol contributes to 2.6 million deaths annually worldwide, representing 4.4% of all global deaths
03
In Europe, the European Heart Network states that 54% of adults have total cholesterol levels above the recommended 5 mmol/L threshold
04
A NHANES survey from 2017-2018 found that 38.7% of U.S. adults had high LDL cholesterol (≥130 mg/dL)
05
Globally, 39% of adults aged 18+ had high cholesterol in 2018 per WHO STEPS survey data
06
In India, the ICMR-INDIAB study reported a prevalence of hypercholesterolemia at 13.9% in urban populations
07
Australian Bureau of Statistics data shows 32% of adults had high total cholesterol (>5.5 mmol/L) in 2011-12
08
In the UK, 59% of adults have cholesterol levels above 5 mmol/L according to BHF
09
Framingham Heart Study offspring cohort indicated 45% prevalence of high cholesterol in middle-aged adults
10
In China, the China Health and Nutrition Survey found 32.1% hypercholesterolemia prevalence in 2009
11
Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) reported 31.1% high LDL-C prevalence
12
In South Africa, 52.6% of adults had total cholesterol >5 mmol/L per WHO STEPS 2016
13
Japanese National Health and Nutrition Survey 2019 showed 27.4% dyslipidemia prevalence
14
In Mexico, ENSANUT 2018 found 47.5% high cholesterol in adults
15
Canadian Heart Health Surveys reported 42% prevalence of high cholesterol in 1986-1992
16
In Germany, DEGS1 survey 2008-2011 indicated 30.8% high total cholesterol
17
Italian Osservatorio Epidemiologico Cardiovascolare reported 38% hypercholesterolemia in adults
18
In Russia, 56.9% of adults had high cholesterol per 2013 survey
19
Swedish National Public Health Survey 2018 showed 25% high cholesterol prevalence
20
In the Netherlands, 60% of adults over 30 have elevated cholesterol per RIVM
21
New Zealand Health Survey 2017/18 found 32% high total cholesterol
22
In Turkey, TEKHARF study 2017 reported 46.2% hypercholesterolemia
23
Saudi Heart Association data indicates 41% prevalence in adults
24
In Egypt, 44.4% of adults have high cholesterol per NCD survey
25
Korean National Health Insurance data 2015 showed 19.6% severe hypercholesterolemia
26
In Iran, 40.2% prevalence from cross-sectional studies meta-analysis
27
Polish NATPOL 2011 study found 52% high cholesterol in adults
28
In Argentina, 34.4% hypercholesterolemia per 2018 survey
29
Norwegian HUNT3 study reported 45% elevated cholesterol
30
In Spain, ESCARVAL study 2008-2010 showed 39% high LDL-C
Interpretation
Epidemiology And Prevalence Interpretation
Across countries, high cholesterol is highly prevalent, with 93 million US adults over age 20 having elevated total cholesterol above 200 mg/dL and WHO estimates showing 39% of adults globally are affected, underscoring how widespread the problem is from an epidemiology and prevalence perspective.
04 · Category
Health Outcomes28 stats
01
High cholesterol increases CVD risk by 2.5-fold per 1 mmol/L LDL rise
02
Each 38.7 mg/dL LDL reduction lowers major vascular events by 22%
03
Low HDL (<40 mg/dL men) triples coronary heart disease risk
04
High cholesterol causes 4 million premature deaths yearly globally
05
Familial hypercholesterolemia untreated leads to 50% MI risk by age 50
06
Statin therapy reduces stroke risk by 21% per 1 mmol/L LDL drop
07
Non-HDL cholesterol >3.37 mmol/L doubles CVD mortality
08
Cholesterol embolization syndrome occurs in 1.4% post-angioplasty
09
High LDL accelerates aortic stenosis progression by 2-fold
10
Hypercholesterolemia increases PAD risk by 2.2-fold
11
In women, high cholesterol raises CVD death risk 4.5-fold post-menopause
12
Lp(a) >50 mg/dL elevates MI risk 2-3 fold
13
Cholesterol gallstones comprise 80% of gallstones in Western populations
14
High triglycerides (>5 mmol/L) increase pancreatitis risk 10-fold
15
Dyslipidemia contributes to 30% of ischemic strokes
16
In FH homozygotes, CVD events occur by age 20 in 75%
17
Remnant cholesterol >1 mmol/L raises CVD risk 40% per unit
18
High cholesterol links to 20% higher dementia risk
19
LDL >160 mg/dL triples carotid plaque progression
20
Statins reduce all-cause mortality by 14% in high cholesterol patients
21
High on-treatment LDL >70 mg/dL has 2-fold recurrent event risk
22
Cholesterol burden predicts 25% AFib risk increase
23
Xanthomas occur in 75% of FH heterozygotes untreated
24
Hypercholesterolemia worsens HF prognosis by 30%
25
LDL particle number >1300 nmol/L doubles CVD risk vs concentration
26
High cholesterol in youth predicts adult CVD 5-fold
27
Optimal total cholesterol <150 mg/dL reduces mortality 50%
28
HDL dysfunction increases MI risk 3-fold despite high levels
Interpretation
Health Outcomes Interpretation
From a Health Outcomes perspective, lowering LDL even modestly has major benefits because a 38.7 mg/dL reduction cuts major vascular events by 22%, while each 1 mmol/L LDL rise increases CVD risk by 2.5-fold.
05 · Category
Risk Factors And Correlates30 stats
01
Daily cholesterol intake averages 300-500 mg in Western diets
02
Obesity increases LDL cholesterol by 10-15% per 10 kg weight gain
03
Smoking raises LDL by 5-10% and lowers HDL by 10%
04
Type 2 diabetes elevates triglycerides and lowers HDL by 20-30%
05
Sedentary lifestyle correlates with 12% higher total cholesterol
06
Family history doubles risk of hypercholesterolemia
07
Postmenopausal women see 10-15% LDL rise due to estrogen decline
08
Trans fat intake raises LDL by 0.03 mmol/L per gram daily
09
Hypertension coexists with high cholesterol in 40% of cases
10
Age over 45 in men or 55 in women increases cholesterol risk by 2-fold
11
South Asian ethnicity has 20% higher dyslipidemia prevalence
12
Alcohol excess lowers HDL but raises triglycerides by 20%
13
Hypothyroidism elevates LDL by 30% via reduced clearance
14
Chronic kidney disease doubles hypercholesterolemia odds
15
Saturated fat >10% calories raises LDL by 10%
16
PCOS increases dyslipidemia risk by 70%
17
HIV infection on ART raises cholesterol by 10-20%
18
Stress hormones increase LDL by 10% acutely
19
Low fiber diet correlates with 15% higher cholesterol absorption
20
Metabolic syndrome present in 50% of high cholesterol patients
21
African American men have 10% lower average HDL than whites
22
Sleep apnea raises cholesterol by 10-15%
23
Corticosteroid use elevates cholesterol 20-30%
24
High glycemic index diets increase triglycerides 20%
25
Rheumatoid arthritis patients have 10% higher LDL
26
Beta-blockers raise triglycerides by 20-50%
27
Pregnancy increases total cholesterol by 25-50% in third trimester
28
Psoriasis doubles dyslipidemia risk
29
Shift work disrupts lipids with 8% higher cholesterol
30
High fructose intake raises LDL 10%
Interpretation
Risk Factors And Correlates Interpretation
Across these risk factors and correlates, lifestyle and metabolic conditions often shift lipid patterns meaningfully, such as obesity increasing LDL by 10 to 15% and smoking lowering HDL by 10 while sedentary living is linked to about 12% higher total cholesterol.
06 · Category
Treatment Efficacy29 stats
01
Statins reduce LDL by 20-60% dose-dependently
02
Ezetimibe adds 15-25% LDL reduction to statin
03
PCSK9 inhibitors lower LDL 50-70% in FH patients
04
Bempedoic acid reduces LDL 18% monotherapy
05
Plant sterols 2g/day lower LDL 10%
06
Niacin raises HDL 15-35% but no CVD benefit
07
Fibrates reduce triglycerides 20-50%
08
Aerobic exercise 150 min/week lowers LDL 5-10%
09
Mediterranean diet reduces LDL 10-15%
10
Soluble fiber 5-10g/day lowers LDL 5%
11
Weight loss 5-10% reduces total cholesterol 10%
12
Omega-3 4g/day lowers triglycerides 30%
13
Lomitapide in FH homozygotes reduces LDL 40-50%
14
Mipomersen ASO lowers LDL 40% in FH
15
Inclisiran siRNA reduces LDL 52% at 17 months
16
Portfolio diet lowers LDL 30% comparable to lovastatin
17
Rosuvastatin 20mg reduces LDL 55%
18
Lifestyle intervention alone lowers cholesterol 10-20% in mild cases
19
Bile acid sequestrants lower LDL 15-30%
20
Smoking cessation increases HDL 10% within 1 year
21
Soy protein 25g/day lowers LDL 3-5%
22
Nuts 1oz/day reduce LDL 5%
23
Green tea catechins lower LDL 5-10 mg/dL
24
Resistant starch intake reduces cholesterol absorption 10%
25
Probiotics lower LDL 5-10% in meta-analysis
26
Garlic supplements reduce total cholesterol 10-15 mg/dL short-term
27
Evolocumab reduces CVD events 20%
28
Alirocumab lowers LDL 62% max
29
Intensive statin doubles plaque regression vs moderate
Interpretation
Treatment Efficacy Interpretation
Across this treatment efficacy set, LDL reductions are consistently large with add-on or advanced therapies, with statins cutting LDL by 20 to 60% and adding ezetimibe or PCSK9 inhibitors pushing totals to roughly 15 to 25% more or 50 to 70% in familial hypercholesterolemia patients.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Cholesterol Statistics. Gitnux. https://gitnux.org/cholesterol-statistics
MLA
Lukas Bauer. "Cholesterol Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cholesterol-statistics.
Chicago
Lukas Bauer. 2026. "Cholesterol Statistics." Gitnux. https://gitnux.org/cholesterol-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level